YMK(300249)
Search documents
华鲲振宇召开人工智能产业链协同发展座谈会
Zheng Quan Shi Bao Wang· 2025-12-03 11:57
人民财讯12月3日电,12月2日,华鲲振宇在成都总部举办成都人工智能上下游产业协同发展供需共链座 谈会。四川国科光电技术厂、成飞集成(002190)科技股份有限公司、依米康(300249)科技集团股份 有限公司等30余家产业链重点企业负责人,以及民生银行成都分行、成都农商银行等金融机构代表围绕 人工智能、基础算力发展与国产化技术应用等核心议题,共商协同创新、聚力发展之道。 ...
依米康(300249) - 关于控股股东部分股份解除质押的公告
2025-12-03 07:52
证券代码:300249 证券简称:依米康 公告编号:2025-089 依米康科技集团股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 | | 证券代码:300249 | | | 证券简称:依米康 | | | 公告编号:2025-089 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 限公司 | | | | | | | | | | | -思勰 | | | | | | | | | | | 投资安 | | | | | | | | | | | 欣十七 | | | | | | | | | | | 号私募 | | | | | | | | | | | 证券投 | | | | | | | | | | | 资基金 | | | | | | | | | | | 合计 | 143,228,173 | 32.52% | 32,810,000 | 22.91% | 7.45% | 15,500,000 | 47.24% | 50,878,375 | ...
2025上半年扭亏但经营现金流转负遭问询 依米康回复
2 1 Shi Ji Jing Ji Bao Dao· 2025-12-02 02:20
Core Viewpoint - The Shenzhen Stock Exchange has issued an inquiry letter to Yimikang regarding its stock issuance to specific targets, focusing on the company's continuous losses from 2022 to 2024 and its financial health indicators [1] Financial Performance - Yimikang reported continuous losses primarily due to a decline in its environmental governance business and a significant reduction in smart engineering revenue [1] - After divesting its environmental business in 2023, the company shifted its focus to the information data sector, resulting in a surge in sales of key equipment (temperature control equipment), leading to a net profit attributable to shareholders of 14.92 million yuan in the first half of 2025 [1] Cash Flow and Liquidity - The negative operating cash flow is attributed to an increase in receivables and higher raw material inventory expenditures, which the company claims is a trend observed in comparable industry peers [1] - As of June 30, 2025, Yimikang's debt-to-asset ratio stood at 81.4%, with the company emphasizing sufficient bank credit and that 88.06% of its current assets are unencumbered [1] Auditor Confirmation - The accounting firm Xinyong Zhonghe confirmed that the reasons for the company's performance changes are reasonable, indicating a significant improvement in operational status, with adequate impairment provisions and compliance with accounting standards [1]
依米康回复深交所定增审核问询函 修订申请文件 事项仍待审核与注册
Xin Lang Cai Jing· 2025-12-01 10:39
Group 1 - The core point of the article is that Yimikang Technology Group Co., Ltd. has completed its response to the Shenzhen Stock Exchange regarding the inquiry letter for issuing shares to specific objects, and has updated its fundraising documents, but the implementation of this matter is still subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the final approval and timing [1][2]. Group 2 - On November 11, 2025, Yimikang received an inquiry letter from the Shenzhen Stock Exchange regarding its application to issue shares to specific objects [1]. - The company, along with relevant intermediaries, has addressed the issues raised in the inquiry letter and updated the fundraising documents accordingly, which have been disclosed on the Giant Tide Information Network [1]. - The company emphasizes that the issuance of shares is contingent upon the completion of the Shenzhen Stock Exchange's review process and obtaining the approval from the China Securities Regulatory Commission [2].
依米康回复深交所问询函:2025年上半年扭亏为盈 境外收入同比增长27.48%
Xin Lang Cai Jing· 2025-12-01 10:39
Core Viewpoint - Yimikang Technology Group Co., Ltd. has successfully turned a profit in the first half of 2025, achieving a net profit of 14.92 million yuan, primarily due to the divestment of loss-making environmental governance business and a focus on core information data sectors [1][2][7]. Performance Fluctuation - The company has shown a trend of "narrowing losses to profitability" from 2022 to the first half of 2025, with net profits of -32.45 million yuan, -216.46 million yuan, and -87.14 million yuan in the previous three years [2]. - In the first half of 2025, the company reported operating revenue of 736.77 million yuan, with key equipment business revenue reaching 474.81 million yuan, accounting for 64.45% of total revenue, and a gross margin of 16.46% [2]. Debt Repayment Ability - As of June 2025, the company's debt-to-asset ratio stands at 81.40%, with a current ratio of 0.97 and a quick ratio of 0.75, all below industry averages [3]. - The company has secured a bank credit line of 625 million yuan, with 189 million yuan unused, and its operating cash flow net amount accounts for 104.93% of operating revenue, indicating sufficient short-term and long-term debt repayment capacity [3]. Overseas Revenue - The company's overseas sales have rapidly increased since 2024, with foreign sales reaching 62.32 million yuan in the first half of 2025, primarily from Malaysia (98.55% of total) and Thailand [4]. - The gross margin for overseas business is 30.33%, significantly higher than the domestic margin of 16.07%, due to strong demand for high-power temperature control equipment in overseas data centers [4]. Accounts Receivable and Inventory - As of June 2025, accounts receivable amounted to 765.91 million yuan, with 55.33% aged within one year, and a bad debt provision ratio of 23.31%, higher than the industry average [5]. - Inventory value stands at 285.10 million yuan, with 67.71% aged within one year, and a write-down provision ratio of 14.95%, also above the industry average, indicating sufficient impairment provisions [5]. Other Important Matters - The company's dealer model accounts for 7.11% of revenue with a gross margin of 35.26%, while subcontracting business represents 7.01% [6]. - The goodwill balance is 2.89 million yuan, with minimal impact from further impairment on performance, and the value of the medical industry park's operating rights is 274.80 million yuan, unaffected by business adjustments [6]. Conclusion - Yimikang indicates a clear trend of performance improvement and enhanced competitiveness in core business areas, with manageable risks [7].
依米康(300249) - 北京市康达律师事务所关于依米康科技集团股份有限公司2025年度向特定对象发行股票的补充法律意见书
2025-12-01 09:12
北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于依米康科技集团股份有限公司 2025 年度向特定对象发行股票的 补充法律意见书 康达股发字[2025]第 0531-1 号 二〇二五年十一月 3-1 补充法律意见书 北京市康达律师事务所 关于依米康科技集团股份有限公司 2025 年度向特定对象发行股票的 补充法律意见书 康达股发字[2025]第 0531-1 号 致:依米康科技集团股份有限公司 本所律师仅对与法律相关的业务事项履行法律专业人士特别的注意义务,对 其他业务事项 ...
依米康(300249) - 申万宏源证券承销保荐有限责任公司关于依米康科技集团股份有限公司创业板向特定对象发行股票之发行保荐书
2025-12-01 09:12
申万宏源证券承销保荐有限责任公司 关于依米康科技集团股份有限公司 创业板向特定对象发行股票 之 发行保荐书 保荐人 2025 年 11 月 申万宏源证券承销保荐有限责任公司(以下简称"申万宏源承销保荐"、 "本保荐人")接受依米康科技集团股份有限公司(以下简称"发行人"、"公 司"、"依米康")的委托,担任其创业板向特定对象发行股票(以下简称"本 次发行")的保荐人。 本保荐人及相关保荐代表人已根据《中华人民共和国公司法》(以下简称 "《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、 《证券发行上市保荐业务管理办法》《上市公司证券发行注册管理办法》(以下 简称"《注册办法》")、《保荐人尽职调查工作准则》等法律法规和中国证监 会及深圳证券交易所的有关规定,诚实守信,勤勉尽责,严格按照依法制定的业 务规则、行业执业规范和道德准则出具发行保荐书,并保证所出具文件的真实性、 准确性和完整性。 3-1-1 第一节 本次证券发行基本情况 一、本次具体负责推荐的保荐代表人 申万宏源证券承销保荐有限责任公司作为依米康科技集团股份有限公司创 业板向特定对象发行股票的保荐人,指派具体负责推荐的保荐代表人为曾 ...
依米康(300249) - 申万宏源证券承销保荐有限责任公司关于依米康科技集团股份有限公司向特定对象发行股票并在创业板上市之上市保荐书
2025-12-01 09:12
申万宏源证券承销保荐有限责任公司 关于依米康科技集团股份有限公司 向特定对象发行股票并在创业板上市之 上市保荐书 保荐人 二零二五年十一月 申万宏源证券承销保荐有限责任公司及其保荐代表人已根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《证券发行上市保荐业务管理办法》(以下简称"《保荐业务管理办法》")、 《上市公司证券发行注册管理办法》(以下简称"《注册管理办法》")、《深圳证券 交易所创业板股票上市规则》(以下简称"《上市规则》")等法律法规和中国证监 会及深圳证券交易所的有关规定,诚实守信,勤勉尽责,严格按照依法制定的业 务规则和行业自律规范出具上市保荐书,并保证所出具文件真实、准确、完整。 现将有关情况报告如下: 2、合并利润表主要数据 | 单位:万元 | | --- | | 项目 | 年 2025 | 1-6 | 月 | 年度 2024 | 年度 2023 | 年度 2022 | | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | | 73,676.88 | | 114,456.31 ...
依米康(300249) - 2025年度向特定对象发行A股股票募集说明书(申报稿)
2025-12-01 09:12
依米康科技集团股份有限公司 四川省成都市高新区科园南二路二号 2025 年度向特定对象发行 A 股股票 募集说明书 (申报稿) 保荐人(主承销商) (新疆乌鲁木齐市高新区(新市区)北京南路 358 号大成国际大厦 20 楼 2004 室) 二零二五年十一月 股票代码:依米康 股票简称:300249 依米康科技集团股份有限公司 2025年度向特定对象发行A股股票募集说明书 声 明 本公司及全体董事、高级管理人员承诺募集说明书及其他信息披露资料不存 在任何虚假记载、误导性陈述或重大遗漏,并对其真实性、准确性及完整性承担 连带赔偿责任。 本公司控股股东承诺募集说明书及其他信息披露资料不存在任何虚假记载、 误导性陈述或重大遗漏,并对其真实性、准确性及完整性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务会计 资料真实、完整。 中国证券监督管理委员会、深圳证券交易所对本次发行所作的任何决定或意 见,均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证, 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何与之相反的声明均属虚假不实陈述。 ...
依米康(300249) - 关于依米康科技集团股份有限公司申请向特定对象发行股票的审核问询函之回复报告
2025-12-01 09:12
关于依米康科技集团股份有限公司 申请向特定对象发行股票的审核问询函 之回复报告 保荐人(主承销商) 申万宏源证券承销保荐有限责任公司 (新疆乌鲁木齐市高新区(新市区)北京南路 358 号大成国际大厦 20 楼 2004 室) 二〇二五年十一月 深圳证券交易所: 贵所于 2025 年 11 月 11 日出具的《关于依米康科技集团股份有限公司申请 向特定对象发行股票的审核问询函(审核函〔2025〕020064 号)(以下简称"《问 询函》")已收悉,依米康科技集团股份有限公司(以下简称"依米康"、"公 司"或"发行人")与申万宏源证券承销保荐有限责任公司(以下简称"保荐 人")、北京市康达律师事务所(以下简称"发行人律师")及信永中和会计师 事务所(特殊普通合伙)(以下简称"发行人会计师")等相关各方对《问询函》 相关问题逐项进行了落实,现对《问询函》回复如下,请审核。 说明: 一、如无特别说明,本回复报告中的简称或名词释义与《募集说明书》中的 相同。 二、本回复报告中的字体代表以下含义: | 《问询函》所列问题 | 黑体 | | --- | --- | | 对《问询函》所列问题的回复 | 宋体 | | 对《募集 ...